Charles Locke

1.9k total citations
54 papers, 1.4k citations indexed

About

Charles Locke is a scholar working on Molecular Biology, Pharmacology and Pharmacology. According to data from OpenAlex, Charles Locke has authored 54 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Pharmacology and 9 papers in Pharmacology. Recurrent topics in Charles Locke's work include Pharmacogenetics and Drug Metabolism (9 papers), Statistical Methods in Clinical Trials (8 papers) and Cardiac electrophysiology and arrhythmias (6 papers). Charles Locke is often cited by papers focused on Pharmacogenetics and Drug Metabolism (9 papers), Statistical Methods in Clinical Trials (8 papers) and Cardiac electrophysiology and arrhythmias (6 papers). Charles Locke collaborates with scholars based in United States, United Kingdom and Egypt. Charles Locke's co-authors include John M. Leonard, G. Richard Granneman, John H. Cavanaugh, Ramanuj Achari, Jonathan Q. Purnell, John D. Brunzell, Walid M. Awni, Alberto Zambon, David Pizzuti and Robert H. Knopp and has published in prestigious journals such as Neurology, Technometrics and Pain.

In The Last Decade

Charles Locke

53 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Charles Locke United States 20 347 309 234 192 189 54 1.4k
Ana Blas‐García Spain 25 567 1.6× 394 1.3× 571 2.4× 374 1.9× 110 0.6× 58 1.7k
Ting Zhu China 24 376 1.1× 144 0.5× 226 1.0× 632 3.3× 114 0.6× 81 1.7k
W. Todd Cade United States 25 167 0.5× 329 1.1× 72 0.3× 711 3.7× 479 2.5× 92 2.6k
Paul Spiers United Kingdom 23 135 0.4× 64 0.2× 64 0.3× 307 1.6× 141 0.7× 67 1.5k
Olivier Tribut France 19 298 0.9× 71 0.2× 123 0.5× 184 1.0× 62 0.3× 48 1.4k
J G Gerber United States 20 187 0.5× 73 0.2× 85 0.4× 216 1.1× 232 1.2× 47 1.2k
Brian Granda United States 18 287 0.8× 100 0.3× 110 0.5× 446 2.3× 45 0.2× 26 1.9k
John H. Cavanaugh United States 23 245 0.7× 60 0.2× 62 0.3× 156 0.8× 145 0.8× 59 1.7k
Inge De Lepeleire United States 28 218 0.6× 43 0.1× 131 0.6× 278 1.4× 480 2.5× 80 2.4k
Carlo Tomino Italy 19 243 0.7× 46 0.1× 106 0.5× 195 1.0× 213 1.1× 70 1.2k

Countries citing papers authored by Charles Locke

Since Specialization
Citations

This map shows the geographic impact of Charles Locke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Locke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Locke more than expected).

Fields of papers citing papers by Charles Locke

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Locke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Locke. The network helps show where Charles Locke may publish in the future.

Co-authorship network of co-authors of Charles Locke

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Locke. A scholar is included among the top collaborators of Charles Locke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Locke. Charles Locke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Othman, Mohamed I. A., Matthew Rosebraugh, Krai Chatamra, Charles Locke, & Sandeep Dutta. (2017). Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa. Journal of Parkinson s Disease. 7(2). 275–278. 32 indexed citations
3.
4.
Nyholm, Dag, Per Odin, Anders Johansson, et al.. (2012). Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease Patients. The AAPS Journal. 15(2). 316–323. 94 indexed citations
5.
Lenz, Robert, Jeffrey D. Baker, Charles Locke, et al.. (2011). The scopolamine model as a pharmacodynamic marker in early drug development. Psychopharmacology. 220(1). 97–107. 47 indexed citations
6.
Xiong, Hao, Robert A. Carr, Charles Locke, et al.. (2007). Dual Effects of Rifampin on the Pharmacokinetics of Atrasentan. The Journal of Clinical Pharmacology. 47(4). 423–429. 26 indexed citations
7.
Reed, Ronald C., Sandeep Dutta, John H. Cavanaugh, Charles Locke, & G. Richard Granneman. (2006). Every-12-hour administration of extended-release divalproex in patients with epilepsy: Impact on plasma valproic acid concentrations. Epilepsy & Behavior. 8(2). 391–396. 13 indexed citations
8.
Karyekar, Chetan S., Rajendra Pradhan, Qin Ji, et al.. (2005). A Phase I Multiple‐Dose Escalation Study Characterizing Pharmacokinetics and Safety of ABT‐578 in Healthy Subjects. The Journal of Clinical Pharmacology. 45(8). 910–918. 10 indexed citations
9.
Karol, Michael D., et al.. (2004). Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules. Clinical Therapeutics. 26(12). 2076–2083. 7 indexed citations
10.
Karol, Michael D., et al.. (2000). Lack of Interaction between Lansoprazole and Propranolol, a Pharmacokinetic and Safety Assessment. The Journal of Clinical Pharmacology. 40(3). 301–308. 7 indexed citations
11.
Ouellet, Danièle, Ann Hsu, Jiang Qian, et al.. (1998). Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. British Journal of Clinical Pharmacology. 46(2). 111–116. 143 indexed citations
12.
Awni, Walid M., John H. Cavanaugh, Philip T. Leese, et al.. (1997). The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine. European Journal of Clinical Pharmacology. 52(1). 49–54. 15 indexed citations
13.
Wong, Shekman, Walid M. Awni, John H. Cavanaugh, et al.. (1995). The Pharmacokinetics of Single Oral Doses of Zileuton 200 to 800mg, its Enantiomers, and its Metabolites, in Normal Healthy Volunteers. Clinical Pharmacokinetics. 29(Supplement 2). 9–21. 24 indexed citations
14.
Braeckman, Rene A., G. Richard Granneman, Charles Locke, et al.. (1995). The Pharmacokinetics of Zileuton in Healthy Young and Elderly Volunteers. Clinical Pharmacokinetics. 29(Supplement 2). 42–48. 31 indexed citations
15.
Peter, John V. St., Rene A. Braeckman, G. Richard Granneman, et al.. (1995). The effect of zileuton on antipyrine and indocyanine green disposition*. Clinical Pharmacology & Therapeutics. 57(3). 299–308. 10 indexed citations
16.
Awni, Walid M., Rene A. Braeckman, Charles Locke, Louise M. Dubé, & G. Richard Granneman. (1995). The Influence of Multiple Oral Doses of Zileuton on the Steady-State Pharmacokinetics of Sulfasalazine and its Metabolites, Sulfapyridine and N-Acetylsulfapyridine. Clinical Pharmacokinetics. 29(Supplement 2). 98–104. 5 indexed citations
17.
Awni, Walid M., Rene A. Braeckman, John H. Cavanaugh, et al.. (1995). The Pharmacokinetic and Pharmacodynamic Interactions between the 5-Lipoxygenase Inhibitor Zileuton and the Cyclo-Oxygenase Inhibitor Naproxen in Human Volunteers. Clinical Pharmacokinetics. 29(Supplement 2). 112–124. 12 indexed citations
18.
Granneman, G. Richard, Rene A. Braeckman, Charles Locke, et al.. (1995). Effect of Zileuton on Theophylline Pharmacokinetics. Clinical Pharmacokinetics. 29(Supplement 2). 77–83. 31 indexed citations
19.
Chu, Sou-Yie, et al.. (1992). Drug‐Food Interaction Potential of Clarithromycin, A New Macrolide Antimicrobial. The Journal of Clinical Pharmacology. 32(1). 32–36. 42 indexed citations
20.
Graves, David A., Charles Locke, Keith T. Muir, & Richard P. Miller. (1989). The influence of assay variability on pharmacokinetic parameter estimation. Journal of Pharmacokinetics and Biopharmaceutics. 17(5). 571–592. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ana Blas‐García Breakdown of academic impact, for papers by Ting Zhu Breakdown of academic impact, for papers by W. Todd Cade Breakdown of academic impact, for papers by Paul Spiers Breakdown of academic impact, for papers by Olivier Tribut Breakdown of academic impact, for papers by J G Gerber Breakdown of academic impact, for papers by Brian Granda Breakdown of academic impact, for papers by John H. Cavanaugh Breakdown of academic impact, for papers by Inge De Lepeleire Breakdown of academic impact, for papers by Carlo Tomino
Rankless by CCL
2026